Scarica l'app Stockscreener
8.95
10.36%
0.84
Pre-mercato:
9.68
0.73
+8.16%
Precedente Chiudi:
$8.11
Aprire:
$8.31
Volume 24 ore:
6.94M
Relative Volume:
4.56
Capitalizzazione di mercato:
$502.41M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-6.938
EPS:
-1.29
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
+22.10%
1M Prestazione:
-5.19%
6M Prestazione:
+9.01%
1 anno Prestazione:
+8.22%
Intervallo 1D:
$8.065
$9.18
Intervallo di 1 settimana:
$7.3546
$9.18
Portata 52W:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Confronta ZVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.95 | 455.26M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Goldman Sachs Group Inc. Has $1.46 Million Stake in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Tamara A. Favorito Acquires 3,175 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Aug Drivers: Is Zevra Therapeutics Inc in a long term uptrendJuly 2025 Institutional & Stepwise Trade Signal Guides - خودرو بانک
Aug Wrap: Is Zevra Therapeutics Inc. trading at a discount2025 Earnings Impact & Low Drawdown Investment Ideas - خودرو بانک
Bear Alert: Can Zevra Therapeutics Inc stock double in the next year2025 Earnings Surprises & Stock Timing and Entry Methods - خودرو بانک
Aug Shorts: What is Zevra Therapeutics Incs market positionEarnings Growth Summary & Long-Term Capital Growth Strategies - خودرو بانک
Zevra Therapeutics (NASDAQ:ZVRA) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Zevra Therapeutics Announces Upcoming Oral Presentation at - GlobeNewswire
Support Test: Will Zevra Therapeutics Inc benefit from geopolitical trends2025 Technical Overview & Verified Chart Pattern Trade Signals - خودرو بانک
Short Squeeze: Can Zevra Therapeutics Inc benefit from deglobalization2025 Momentum Check & Verified Swing Trading Watchlists - خودرو بانک
Alvin Shih Adds To Zevra Therapeutics Holding - 富途牛牛
Zevra Therapeutics Announces Presentations on MIPLYFFA® and OLPRUVA® at Upcoming International Conferences - Quiver Quantitative
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sod - GlobeNewswire
First Drug to Stop NPC Disease Progression: Zevra's MIPLYFFA Shows Breakthrough Results in 270 Patients - Stock Titan
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - Yahoo Finance
RSI Check: Is Zevra Therapeutics Inc. in a long term uptrendQuarterly Earnings Summary & AI Driven Price Predictions - خودرو بانک
Insider Buying: Tamara Favorito Acquires Shares of Zevra Therapeutics Inc (ZVRA) - GuruFocus
A Fresh Look at Zevra Therapeutics (ZVRA) Valuation Following New MIPLYFFA Data Release - Yahoo Finance
Alvin Shih At Zevra Therapeutics Tops Up Holding By US$158k - simplywall.st
Published on: 2025-09-16 13:04:37 - khodrobank.com
Woodline Partners LP Raises Holdings in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics gains amid takeover speculation - MSN
Insider Buying: Alvin Shih Acquires 20,000 Shares of Zevra Therapeutics Inc (ZVRA) - GuruFocus
Insider Trends: Can Zevra Therapeutics Inc sustain earnings growth2025 Growth vs Value & Accurate Intraday Trade Tips - خودرو بانک
Stock Report: What is the next catalyst for Zevra Therapeutics IncWeekly Profit Recap & Proven Capital Preservation Methods - خودرو بانک
Insider Trends: What is the next catalyst for Zevra Therapeutics IncSwing Trade & Fast Gaining Stock Strategy Reports - خودرو بانک
Aug Mood: Is Zevra Therapeutics Inc backed by strong institutional buyingJuly 2025 Price Swings & AI Powered Market Entry Strategies - خودرو بانک
Will Zevra Therapeutics Inc. rebound enough to break evenWeekly Trade Report & Low Risk Entry Point Guides - newser.com
What technical models suggest about Zevra Therapeutics Inc.’s comeback2025 Market WrapUp & Safe Capital Preservation Plans - newser.com
Visual trend scoring systems applied to Zevra Therapeutics Inc.2025 Growth vs Value & Consistent Income Trade Recommendations - newser.com
Zevra Therapeutics (ZVRA): Evaluating Valuation After Positive MIPLYFFA Clinical Data Spurs Investor Interest - Sahm
Is Zevra Therapeutics Inc. forming a bottoming baseJuly 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Is a relief rally coming for Zevra Therapeutics Inc. holdersBull Run & Free Safe Entry Trade Signal Reports - newser.com
Do Zevra Therapeutics' (ZVRA) New MIPLYFFA Data Reshape the Rare Disease Innovation Narrative? - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Large Growth in Short Interest - MarketBeat
Adage Capital Partners GP L.L.C. Reduces Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Does Zevra Therapeutics Inc. have high return on assets2025 Market Overview & Growth Oriented Trading Recommendations - Lancaster City Council
Is Zevra Therapeutics Inc. stock a good dividend stockBuy Signal & Reliable Momentum Entry Alerts - Lancaster City Council
Moving Average Crossover Confirms Uptrend in Zevra Therapeutics Inc.July 2025 Intraday Action & Community Consensus Picks - beatles.ru
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash - simplywall.st
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - 富途牛牛
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus PT from Analysts - MarketBeat
Is Zevra Therapeutics Inc. a strong growth stockWeekly Trade Report & Low Drawdown Momentum Trade Ideas - خودرو بانک
Retirement Planning Co of New England Inc. Purchases 35,348 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLC - MarketBeat
What’s the recovery path for long term holders of Zevra Therapeutics Inc.Market Activity Recap & Free Community Consensus Stock Picks - Newser
Is Zevra Therapeutics Inc. a good ESG investmentGap Down & Free Verified High Yield Trade Plans - خودرو بانک
What analysts say about Zevra Therapeutics Inc. stockWeekly Profit Report & High Return Trade Opportunity Guides - خودرو بانک
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.30%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):